Structure via PubChem · Public domain (PubChem)
indantadol
Sign in to saveIndantadol (developmental code names CHF-3381, V-3381) is a drug of the 2-aminoindane family which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi. It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor, and as a low affinity, non-competitive NMDA receptor antagonist. A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in
Chemical data
- Formula
- C11H14N2O
- Molecular weight
- 190.24 g/mol
- IUPAC name
- 2-(2,3-dihydro-1H-inden-2-ylamino)acetamide
- SMILES
- C1C(CC2=CC=CC=C21)NCC(=O)N
- InChIKey
- MNLULKBKWKTZPE-UHFFFAOYSA-N
- XLogP
- 0.8
- Polar surface area
- 55.1 Ų
- H-bond donors
- 2
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 190.110613068
Show 2 more facts
- chemical formula
- C₁₁H₁₄N₂O
- canonical SMILES
- C1C(CC2=CC=CC=C21)NCC(=O)N
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Indantadol (developmental code names CHF-3381, V-3381) is a drug of the 2-aminoindane family which was formerly being investigated as an anticonvulsant and neuroprotective and is now under development for the treatment of neuropathic pain and chronic cough in Europe by Vernalis and Chiesi. It acts as a competitive, reversible, and non-selective monoamine oxidase inhibitor, and as a low affinity, non-competitive NMDA receptor antagonist. A pilot study of indantadol for chronic cough was initiated in October 2009 and in April 2010 it failed to achieve significant efficacy in neuropathic pain in phase IIb clinical trials.
== See also == Substituted 2-aminoindane Glycine
Excerpted from Wikipedia’s “indantadol” article, available under the CC BY-SA 4.0 licence.